论文部分内容阅读
目的:探讨莫沙必利与多潘立酮治疗功能性消化不良的临床效果。方法:选取2015/3-2017/3我院收治的100例功能性消化不良患者作为研究对象,根据治疗药物差异将全部患者分成莫沙必利组合多潘立酮组,对比两组患者的临床效果。结果:莫沙必利组患者在功能性的消化不良方面的治疗总有效率和胃排空率显著高于多潘立酮组,不良反应发生率低于多潘立酮组,两组差异具备统计学意义(P<0.05)。结论:莫沙必利在功能性消化不良患者的治疗当中有着突出疗效,能够显著改善患者的各项临床症状,提高胃肠动力,并且具有不良反应低、胃排空率高以及耐受性好的特点,值得推广。
Objective: To investigate the clinical efficacy of mosapride and domperidone in the treatment of functional dyspepsia. METHODS: A total of 100 patients with functional dyspepsia treated in our hospital from 2015/3 to 2017/3 were selected as study subjects. All patients were divided into mosapride and domperidone groups according to the difference of therapeutic drugs. The clinical effects were compared between the two groups. Results: The total effective rate and gastric emptying rate of mosapride group in functional dyspepsia were significantly higher than those in domperidone group, and the incidence of adverse reactions was lower than that in domperidone group, with significant difference between the two groups (P < 0.05). Conclusion: Mosapride has a significant effect in the treatment of patients with functional dyspepsia, which can significantly improve the clinical symptoms and gastrointestinal motility in patients with low adverse reactions, high rate of gastric emptying and good tolerance The characteristics of worth promoting.